. 2021 Sep 21;17:128–138. doi: 10.1016/j.ijpddr.2021.09.001

Table 2.

Studies on the use of nitazoxanide.

Study	Population	Size	Disease severity	Regimen	Comparison	Follow up period	Clinical improvement^a	Parasite clearance^b
Doumbo et al. (1997)	>12 yo with advanced HIV	14	All intensity	500 mg BID for 7 days	None	Days 7 and 14	64% (9/14)	57% (8/14)
Ali and Kumar (2015)	>16 yo healthy individuals	58	All intensity	500 mg BID for 7 days	None	Day 14	100%	N/A
Rossignol (2006)	≥3 yo with HIV	357	All intensity	500–1500 mg BID for maximum 30 days	None	Weeks 1, 2, 4	59% (209/357)	33% (116/357)
Rossignol et al. (2001)	1-65 yo healthy individuals	99	All intensity	100 mg (1–3 yo), or 200 mg (4–11 yo), or 500 mg (adults) BID for 3 days	Placebo	Day 7	80% (39/49) vs. 41% (20/49)^a	67% (33/49) vs. 22% (11/50)^b
Amadi et al. (2002)	1-8 yo with HIV or healthy individuals	96	All intensity	100 mg BID for 3 days	Placebo	Day 7	HIV: 8% (2/25) vs. 25% (6/24)^b Non-HIV: 56% (14/25) vs. 23% (5/22)	HIV: 16% (4/25) vs. 21% (5/24)^b Non-HIV: 52% (13/25) vs. 14% (3/22)
Abaza et al. (2016)	1-12 yo immunocompromised and immunocompetent individuals	120	All intensity	100 mg (<3yo), or 200 mg (>3 yo) BID for 3–4 days (ICT), or 7–28 days (ICZ)	Placebo	At the end of treatment	Immunocompromised: 63% (19/30) vs. 10% (3/30)^a Immunocompetent: 97% (29/30) vs. 53% (16/30)^a	Immunocompromised: 53% (16/30) vs. 23 (7/30)^a Immunocompetent: 93% (28/30) vs. 43% (13/30)^a
Rossignol et al. (2006)	≥12 yo healthy individuals	86	All intensity	500 mg BID for 3 days	Placebo	Days 7 and 10	92% (54/59) vs. 41% (11/27)^a	92% (54/59) vs. 37% (10/27)^a
Amadi et al. (2009)	1-11 yo with HIV	52	All intensity	200 mg (1–3 yo), or 400 mg (4–11 yo) BID for 28 days	Placebo	Every other day until parasite clearance	42% (11/26) vs. 35% (8/26)^b	27% (7/26) vs. 35% (8/26)^b
Rossignol et al. (1998)	18-65 yo with HIV	54	All intensity	500 mg BID for 14 days	Nitazoxanide 1 g BID for 14 days and placebo	Days 7, 15, 22 and 29	63% (12/19) vs. 60% (9/15) vs. 50% (10/20)^a	63% (12/19) vs. 67% (10/15) vs. 25% (5/20)^a
Hussien et al. (2013)	6 mo to 10 yo with malnutrition	135	All intensity	100 mg (<3yo), or 200 mg (>3 yo) BID for 3 days	Paromomycin 25 mg/kg/d for 14 days	At the end of treatment	87% (39/45) vs. 69% (31/45)^a	87% (39/45) vs. 69% (31/45)^a

^aP < 0.05.

^bNot statistically significant.

NS: not statistically significant.

Either abatement of diarrhea or reduced stool frequency or volume.

Either complete eradication or reduction of oocyst number.